Quantitative Phosphoproteomics Analysis Uncovers PAK2- and CDK1-Mediated Malignant Signaling Pathways in Clear Cell Renal Cell Carcinoma.
Male
Humans
Female
Carcinoma, Renal Cell
/ genetics
CDC2 Protein Kinase
/ metabolism
p21-Activated Kinases
/ metabolism
Vascular Endothelial Growth Factor A
/ metabolism
Phosphopeptides
/ metabolism
Cell Line, Tumor
Kidney Neoplasms
/ genetics
Signal Transduction
Cell Proliferation
Gene Expression Regulation, Neoplastic
PAK2
drug targets
phosphoproteomics
renal cell carcinoma
signaling pathways
Journal
Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
12
09
2021
revised:
23
08
2022
accepted:
19
09
2022
pubmed:
25
9
2022
medline:
29
11
2022
entrez:
24
9
2022
Statut:
ppublish
Résumé
Clear cell Renal Cell Carcinoma (ccRCC) is among the 10 most common cancers in both men and women and causes more than 140,000 deaths worldwide every year. In order to elucidate the underlying molecular mechanisms orchestrated by phosphorylation modifications, we performed a comprehensive quantitative phosphoproteomics characterization of ccRCC tumor and normal adjacent tissues. Here, we identified 16,253 phosphopeptides, of which more than 9000 were singly quantified. Our in-depth analysis revealed 600 phosphopeptides to be significantly differentially regulated between tumor and normal tissues. Moreover, our data revealed that significantly up-regulated phosphoproteins are associated with protein synthesis and cytoskeletal re-organization which suggests proliferative and migratory behavior of renal tumors. This is supported by a mesenchymal profile of ccRCC phosphorylation events. Our rigorous characterization of the renal phosphoproteome also suggests that both epidermal growth factor receptor and vascular endothelial growth factor receptor are important mediators of phospho signaling in RCC pathogenesis. Furthermore, we determined the kinases p21-activated kinase 2, cyclin-dependent kinase 1 and c-Jun N-terminal kinase 1 to be master kinases that are responsible for phosphorylation of many substrates associated with cell proliferation, inflammation and migration. Moreover, high expression of p21-activated kinase 2 is associated with worse survival outcome of ccRCC patients. These master kinases are targetable by inhibitory drugs such as fostamatinib, minocycline, tamoxifen and bosutinib which can serve as novel therapeutic agents for ccRCC treatment.
Identifiants
pubmed: 36152754
pii: S1535-9476(22)00225-0
doi: 10.1016/j.mcpro.2022.100417
pmc: PMC9637947
pii:
doi:
Substances chimiques
CDC2 Protein Kinase
EC 2.7.11.22
p21-Activated Kinases
EC 2.7.11.1
Vascular Endothelial Growth Factor A
0
Phosphopeptides
0
PAK2 protein, human
EC 2.7.11.1
CDK1 protein, human
EC 2.7.11.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100417Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare no competing interests.